Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral palonosetron 0.75 mg for prevention of chemotherapy-induced nausea and vomiting during repeated cycles of moderately emetogenic chemotherapy
2005-001944-21Phase 3Completed
- Sponsor
- Helsinn
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of palonosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Helsinn. Primary endpoint: Safety assessment. Started Aug 2005; status: completed.
02
Drugs
palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2005-001944-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001944-21.